Soluble VEGFR-1: a new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?).
UMR8638 CNRS, UFR de Pharmacie, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie, Paris, France; Centre d'étude et de recours sur les inhibiteurs de l'angiogénèse (CERIA), Paris, France.
A
A
Thomas-Schoemann
B
B
Blanchet
P
P
Boudou-Rouquette
J L
JL
Golmard
G
G
Noé
C
C
Chenevier-Gobeaux
C
C
Lebbe
C
C
Pages
J P
JP
Durand
J
J
Alexandre
F
F
Goldwasser
J
J
Guibourdenche
M
M
Vidal
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D042702:Angiopoietin-2 / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000097:blood*
D020533:Angiogenesis Inhibitors; D042702:Angiopoietin-2; D010671:Phenylurea Compounds; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D040301:Vascular Endothelial Growth Factor Receptor-2